Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mNGF for Cognitive Decline in Cerebral Small Vessel Disease
NCT04041349Phase 4Unknown
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Sep 2019
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mouse nerve growth factor in Cerebral Small Vessel Disease (CSVD) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognition at 3 months. Status: unknown.
02
Drugs
mouse nerve growth factor
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT04041349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041349.